Monday, April 30, 2018 - 07:00

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 29, 2018, at 10:00 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

The Notice of Meeting of this Shareholders’ Meeting was published on April 20, 2018, in the French official legal bulletin (“BALO”). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available on the Company’s website.

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be published on the Company’s website as of today.

The 2017 Reference Document (in French) and Financial Report (included in the Reference Document) was released on April 25, 2018 under number D.18-0393, and is available on the website of the Company (http://www.innate-pharma.com) as well as on the website of the AMF, the French stock-market authorities (www.amf-france.org). Hard copies are available upon request to the investor relations department of the Company.

An English translation of the 2017 Reference Document will be made available on Innate Pharma’s website during the month of May 2018.

 

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to investors@innate-pharma.com).

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French “Code de Commerce”) by sending a request:

  • by regular mail to Innate Pharma, Shareholders Services, 117 avenue de Luminy, BP 30191, F-13009 Marseilles, France or
  • by e-mail to investors@innate-pharma.com.

 

AttachmentSize
PR in English80.05 KB
CP en français80.17 KB
Reference Document 20174.41 MB